Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Revenue of Aadi Bioscience, Inc. (AADI)
Revenue in 2023 (TTM): $24.35 M
According to Aadi Bioscience, Inc.'s latest financial reports the company's current revenue (TTM) is $24.35 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Aadi Bioscience, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $24.35 M | $21.55 M | $-71,764,000 | $-65,765,000 | $-65,765,000 |
| 2022 | $15.22 M | $13.88 M | $-56,559,000 | $-60,513,000 | $-57,010,000 |
| 2021 | $1000 K | $724 K | $-35,463,000 | $-110,088,000 | $-110,090,000 |
| 2020 | $14 M | $13.82 M | $-2,652,000 | $-3,476,000 | $-3,478,000 |
| 2019 | $749 K | $672.5 K | $-22,504,090 | $-23,270,514 | $-23,270,514 |
| 2018 | $20.16 M | $20.16 M | $-11,134,550 | $-10,396,635 | $-10,396,635 |
| 2017 | $ | $-51,268 | $-21,337,270 | $-21,400,606 | $-21,400,606 |
| 2016 | $ | $-69,673 | $-16,563,910 | $-16,983,511 | $-16,983,511 |
| 2015 | $ | $-57,977 | $-17,428,580 | $-17,070,223 | $-17,070,223 |
| 2014 | $ | $-23,972 | $-22,824 | $-28,701 | $-28,701 |
| 2013 | $ | $-22,824 | $-22,391 | $-27,365 | $-27,365 |
| 2012 | $ | $-22,391 | $-23,585 | $-27,185 | $-27,185 |
| 2011 | $ | $-23,585 | $-20,509 | $-22,395 | $-22,395 |
| 2010 | $ | $-20,509 | $-41,018 | $-22,395 | $-22,395 |
| 2009 | $ | $ | $ | $ | $ |
| 2008 | $ | $ | $-33,623 | $-33,623 | $-33,623 |